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Abstract
Background: Median overall survival (OS) of patients with melanoma brain metastases (MBM) is usually 6 months
or less. There are rare reports of patients with treated MBM who survived for years. These outlier cases represent
valuable opportunities to study the somatic and germline factors that may have influenced patient outcome and
led to extended survival.
Case presentation: Here we report the clinical scenario of a 67 year old man with a recurrent brain metastasis
from melanoma who has survived over 12 years post-resection. We review the literature relating to clinical and
molecular variables associated with long term survival post-brain metastasis. We present the somatic characteristics
of this individual patient’s tumor as well as an analysis of inherited genetic variants related to immune function.
The patient’s resected brain tumor is BRAF V600E mutated, NRAS wild type (WT), and TERT C250T mutated. The
patient is a carrier of germline variants in immunomodulatory loci associated with prolonged survival.
Conclusions: Our data suggest that genetic variants in immunomodulatory loci may partially contribute to this
patient’s unusually favorable outcome and should not be overlooked. With further and future investigation,
knowledge of inherited single nucleotide polymorphisms (SNPs) may provide clinicians with more individualized
prognostic information for melanoma patients, with potential implications for surveillance strategies and
therapeutic interventions.
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Background
Several published case reports document extended survival
(defined as > 3 years) in melanoma brain metastasis (MBM)
patients who had multiple brain metastases and/or concur-
rent extracranial disease [1, 2], however only two published
case reports document extended survival of patients treated
for a brain-only metastasis [3, 4]. There is no literature to
our knowledge reporting on the molecular analysis of a
long term survivor’s MBM.
We describe the case of a patient who was enrolled in the
New York University (NYU) Interdisciplinary Melanoma
Program biorepository database at the time of primary
diagnosis and was actively followed up by protocol driven,
institutional review board (IRB) approved guidelines who
developed a single MBM and did not respond to initial
gamma knife therapy. He subsequently underwent surgical
resection and remained disease-free for 6 months before
the brain metastasis recurred and required re-resection. As
a result of the availability of tissue from his primary
melanoma, the metastases to the brain, and blood
samples, we had the opportunity to perform molecular
and genetic analyses to investigate tumor- and host-based
characteristics that might explain the unexpectedly
prolonged survival of this patient.* Correspondence: Iman.Osman@nyumc.org
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Materials and methods
DNA isolation and mutation profiling
DNA was isolated from formalin-fixed paraffin embedded
(FFPE) tumor sections of the resected brain metastasis
using the BiOstic FFPE tissue deoxyribonucleic acid (DNA)
isolation kit (MO BIO, Carlsbad, CA). The mulitplex SNaP-
shot assay was used to detect mutations in v-Raf murine
sarcoma viral oncogene homolog B (BRAF) (V600), neuro-
blastoma RAS viral (v-Ras) oncogene homolog (NRAS)
(Q61), and the telomerase reverse transcriptase (TERT)
promoter (C228T (−124C >T) and C250T (−146C >T)).
Germline analysis
The patient was included in a recent analysis testing the
association of 72 single nucleotide polymorphisms (SNPs)
tagging 33 interleukin genes and 11 cytokine regulatory
genes (using Haploview Tagger) with melanoma survival in
1022 cutaneous melanoma patients [5, 6]. SNP genotyping
was performed using the MassARRAY iPLEX platform.
Associations between immunomodulatory SNPs and
recurrence-free survival (RFS) and overall survival (OS) was
tested using Cox models.
Case presentation
The patient is a 67 year old man with a history of asthma
and seasonal allergies who developed a pigmented lesion
on his lower back. The lesion was excised and showed a
non-ulcerated, 3.92 mm thick invasive melanoma with 2
mitoses per square millimeter, non-brisk tumor-infiltrating
lymphocytes (TILs), and partial regression (Fig. 1). There
was no lymphovascular invasion. Wide excision showed
negative margins and no residual melanoma. A left
inguinal sentinel lymph node biopsy was negative, and
the right inguinal sentinel lymph node contained a
0.15 mm micrometastatic focus of melanoma in the
subcapsular region. There was no evidence of distant
disease at diagnosis and AJCC staging was determined
to be stage IIIA (T3aN1aM0).
The patient received one year of adjuvant high dose
interferon-alfa (IFNα) with 20 million units/m2 as
intravenous induction therapy followed by maintenance
therapy with 10 million units/m2 subcutaneously three
times per week.
The patient underwent routine clinical exams and
surveillance imaging at pre-specified intervals. A year and a
half after completing adjuvant IFNα, surveillance imaging
with a brain computed tomography (CT) scan showed a
1.3 cm brain metastasis in the right parietal lobe without
mass effect or cerebral edema (Fig. 2a). He was referred to
a neurosurgeon at our institution and underwent gamma
knife of the single brain metastasis. Six weeks post-gamma
knife, follow-up brain magnetic resonance imaging (MRI)
demonstrated an enlarging hemorrhagic right parietal mass
measuring 4 cm with vasogenic edema (Fig. 2b). The
patient underwent right parietal craniotomy, with the
pathology revealing metastatic melanoma (Fig. 3) positive
for S100, human melanoma black 45 (HMB-45), and
variable mindbomb E3 ubiquitin protein ligase 1 (MIB1)
staining. Post-operative MRI imaging documented total
resection. He recovered well from surgery, was maintained
on levetiracetam for seizure prophylaxis, returned to work,
and continued follow-up with the medical oncologist and
neurosurgeon.
Six months post-craniotomy, the patient presented with
focal seizure activity and was found to have a new enhan-
cing right parietal mass measuring 1.7 × 2.1 × 1.5 cm with
surrounding vasogenic edema (imaging unavailable). He
underwent re-resection of the mass, and pathology was
consistent with recurrent melanoma. Radiographic staging
showed no evidence of extracranial metastases. He under-
went a 6 month course of adjuvant therapy with temozolo-
mide 200 mg/m2 daily for 5 days, every 28 days.
After completing temozolomide, the patient continued
to undergo surveillance brain MRIs every 6 months which
was extended to yearly intervals for a total of 10 years. He
had no further evidence of melanoma recurrence and con-
tinues to have regular follow-up with his medical
oncologist and his dermatologist. He remains melanoma-
free over 12 years post brain metastasis resection (Fig. 2c).
The patient’s resected brain tumor is BRAF V600E
mutated, NRAS wild type (WT), and TERT C250T mutated
(Fig. 4). The patient is a carrier of germline variants in
Fig. 1 Photomicrograph of H&E stained primary nodular melanoma at (a) low and (b) high magnification showing nests of atypical melanocyte
proliferationsmalignant melanoma tumor cells. The scale bar represents 4 mm for panel A and 125 μM for panel B
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immunomodulatory loci associated with prolonged
survival. We found a significant association with mel-
anoma OS for 2 independent genetic variants
(rs3024493, r222202) in the interleukin locus at
1q32.1, mapping in the region of interleukin 10
(IL10) [5]. As noted in Table 1, for these 2 variants,
the patient carries the genotypes that associate with
significantly extended OS in a population-level
analysis.
Discussion
In 2014, there were over 76,000 new melanoma cases
and over 9000 melanoma deaths in the United States [7].
The incidence of MBM ranges from 10 %–50 % in
clinical population-based studies [8, 9] and 45 %–75 %
in autopsy series [10]; however, incidence is increasing
due to improved MRI accessibility and requirements for
baseline brain imaging in melanoma clinical trials [11].
Multiple MBM are more common than single brain
metastases [10]. Independent risk predictors for MBM
in the primary tumor include location (trunk, head and
neck, or mucosa) and presence of ulceration [12].
Median OS from the time of diagnosis of MBM is less
than 12 months, depending on the number of metastases,
the extracranial disease burden, and the administered
treatment. Survival rates at 6 months, 1 year, and 5 years
have been reported as low as 35 %, 20 %, and 5 %, respect-
ively [8, 12, 13]. Post-MBM survival is 12 months for pa-
tients with a solitary MBM compared to only 4 to
6 months for patients with co-existing extracranial disease
[12], which represents approximately 50–60 % of patients
with MBM. Factors significantly associated with worse OS
include age greater than 65, presence of extracranial
disease at time of brain metastasis diagnosis, increasing
number of brain metastases, frontal lobe involvement,
bilateral involvement, presence of neurological symptoms,
weakness, and fatigue [8, 12].
This patient initially presented with stage IIIA melanoma,
which carries a high risk of future recurrence and distant
metastases, particularly in the first three years after diagno-
sis. Five year recurrence rates at any site for stage IIIA, IIIB,
and IIIC are 48 %, 71 %, and 85 %, respectively [14]. The
National Comprehensive Cancer Network (NCCN) guide-
lines recommend that patients with initially diagnosed stage
IIB-IV melanomas who were fully resected undergo clinical
evaluation and physical exam every 3 to 6 months for
2 years and then every 3 to 12 months for the following
2 years, with cross sectional imaging and brain MRI to be
considered yearly as a category 2B recommendation. Risk
of recurrence in the brain as the first site has been reported
as only 5 % for stage IIIA melanoma, although this observa-
tion is impacted by surveillance practices [14]. Most
Fig. 2 Coronal contrast-enhanced MRI brain images showing (a) initial 1.3 cm right parietal lobe metastasis without mass effect or cerebral edema; (b)
enlarging 4 cm hemorrhagic right parietal mass with vasogenic edema 6 weeks post-gamma knife; (c) no evidence of brain metastases 12 years
after resection
Fig. 3 Photomicrographs of H & E stained right parietal lobe mass excision at (a) low and (b) high magnification. The scale bar represents
400 μM for panel a and 50 μM for panel b. on (A) low and (B) high magnification demonstrating metastatic melanoma with non-brisk TILs and
areas of mild to moderate hemorrhage
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recurrences are discovered within 5 years after initial diag-
nosis, so surveillance imaging is not recommended beyond
this time point [15].
In this patient’s case, adherence to surveillance imaging
recommendations identified an asymptomatic solitary brain
metastasis that was not yet clinically evident. However,
negative imaging studies at a single point in time are
unfortunately poor predictors of future metastatic spread,
which could theoretically occur at any time. Identification
of biomarkers that predict risk of future recurrence or site-
specific metastasis, for example to the brain, would aid in
identification of patients who may require more rigorous
surveillance or who may benefit most from adjuvant
therapies.
There is limited published data on the molecular alter-
ations associated with MBM, although in general, debate in
the literature exists as to whether BRAF and/or NRAS
mutated melanomas are associated with worse survival
outcomes compared to WT tumors [16–18]. Furthermore,
the available data may be confounded by prolonged survival
in MBM patients treated with BRAF inhibitors [19]. TERT
promoter mutations are known to be more common in
BRAF or NRAS mutated tumors compared to WT melano-
mas and trend towards worse OS [20], however the role of
TERT mutations in MBM is also unknown.
Chen et al. analyzed 16 pairs of matched brain and
extracranial melanoma metastases for recurrent “hotspot”
mutations known to be influential in cancer. BRAF V600E
and NRAS Q61K mutations were found in 7/16 (44 %)
and 3/16 (19 %) patients, respectively, with 100 %
concordance between the matched brain and extracranial
metastases. Copy number variation (CNV) analysis of 10
MBM found large chromosomal gains (>35 %) and losses
with similar frequencies found in the paired extracranial
metastases, however overall there were no overlapping
CNV profiles among the MBM. Interestingly, protein
expression profiling of 7 pairs of matched tumors demon-
strated MBM to have overexpression of proteins involved
in the phosphatidylinositol 3-kinase (PI3K)/v-akt murine
thymoma viral oncogene homolog (AKT) pathways
including AKT_pS473, GSK3β_pS9, GSK3α/β _pS21/S9,
and PRAS40_pT246 [21]. In this manner, identifying
molecular features unique to MBM, which represents a
significant therapeutic challenge, can reveal signaling
pathways implicated in MBM pathogenesis and suggest
targets for “organ-specific therapy” to the brain [21].
While it is unclear whether the BRAF or TERT mutations
in this patient’s tumor had an impact on his early brain-
only recurrence or his eventual prolonged survival, ongoing
investigation is needed to understand the implications of
MBM somatic mutational profiles.
The patient is a carrier of germline variants in immu-
nomodulatory loci associated with prolonged survival
(Table 1), proposing another suggestive explanation of
his unusual outcome. Notably, the low penetrant effect
of these variants clearly indicates that the patient’s
favorable outcome is unlikely to be attributed solely to
the effect of the tested SNPs and that other genetic or
non-genetic factors will impact these associations.
IL-10 has traditionally been considered an immuno-
suppressive cytokine, associated with more aggressive
melanoma tumor progression [5, 22]. In our recent study,
rs3024493 correlated with decreased IL-10 secretion by
CD4+ T-cells in additive fashion (expression dependent on
the dosage of minor allele). However, the association with
more favorable OS was observed only in heterozygotes that
associate with mid-level secretion of IL-10 [5]. This may
further support the recent hypothesis that IL-10 also exerts
immunostimulatory activities, as recently demonstrated
in molecular studies suggesting IL-10 stimulation of
Fig. 4 Multiplex SNaPshot assay performed on resected brain metastasis demonstrating the tumor to be BRAF V600E mutant and NRAS wild
type. Color codes: green = A, red = T, black = C, blue = G
Table 1 Patient’s genotypes found to be associated with





rs3024493 IL10 GT 0.58; p = 0.00069
rs222202 IL10 CT 0.58; p = 0.0042
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interferon-gamma [23]. It is possible that this and
other immunological mechanisms impact the effect of
associated genetic variants in the IL10 locus. Hence,
while the two germline variants show promising cap-
acity for personalized prediction of unusual outcomes
of the studied patient, their translation into clinical
practice will strongly depend on the completion of
more comprehensive genetic and functional studies in
the future.
Conclusions
In conclusion, we report the somatic and germline
characteristics of a patient with a treated MBM who
exceeded survival expectations. We highlight how data
from molecular tumor profiling and genetic variant
analysis may assist in understanding a patient’s clinical
course. The patient’s brain metastasis was a BRAF V600E
mutated, NRAS WT, TERT C250T mutated tumor with
evidence of germline SNPs that may be associated with
improved OS. We underscore the substantial role of the
immune system in regulating tumor control or progression.
For example, we illustrate the potential impact of the inter-
leukin pathway in augmenting immune activation, as the
patient carries a germline variant in the interleukin locus at
IL10, which may partially contribute to the patient’s
favorable outcome. Of note, this patient also received
temozolomide post-MBM resection. While temozolomide
has been associated with intracranial responses in patients
with unresected, non-irradiated MBM, its low response
rates suggest that it is unlikely to entirely account for this
patient’s outcome [24]. Additionally, although the brain
metastasis is BRAF V600E mutated, this molecular profiling
was performed retroactively for research purposes. At the
time of the brain metastasis diagnosis, BRAF inhibitors
were not approved by the United States Food and Drug
Administration and thus neither BRAF testing nor BRAF
inhibitor therapy represented a standard of care. BRAF
inhibitors by present standards are typically utilized in
melanoma patients who are symptomatic due to high
tumor burden, rather than in patients who achieve “no
evidence of disease” status after surgical resection of an
isolated metastasis.
Molecular profiling of tumors is becoming a standard
of care in breast, colon, and lung cancers as well as in
melanoma. Cancer care is now largely shifting towards a
personalized medicine approach. This case demonstrates
the importance of somatic and germline analyses that
can be a source of guidance in a personalized under-
standing of patient prognosis and tumor biology.
Consent
Written informed consent was obtained from the
patient for study of his tissue and for publication of
patient-related data in accordance with the New York
University Interdisciplinary Melanoma Cooperative Group
protocol for patient enrollment and informed consent,
which is approved by the NYU IRB. A copy of the consent
is available for review.
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